Venture Rounds Help Promedior's Lead Program In Multiple Indications
Executive Summary
Roughly a year after raising $15 million in a Series B financing, Promedior announced it had raised another $12 million in a Series C round on March 16, giving the company enough of a financial runway to advance its lead program into multiple indications
You may also be interested in...
FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials
Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain
FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials
Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain
Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF
Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review